Charles River Laboratories International, Inc. (NYSE:CRL) Stock Holdings Reduced by Horizon Kinetics Asset Management LLC

Horizon Kinetics Asset Management LLC lowered its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 47.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 59,840 shares of the medical research company's stock after selling 54,922 shares during the quarter. Horizon Kinetics Asset Management LLC owned about 0.12% of Charles River Laboratories International worth $11,046,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of CRL. Cibc World Markets Corp raised its position in shares of Charles River Laboratories International by 16.1% during the 4th quarter. Cibc World Markets Corp now owns 8,086 shares of the medical research company's stock valued at $1,493,000 after acquiring an additional 1,124 shares in the last quarter. Hilton Capital Management LLC increased its stake in Charles River Laboratories International by 5.0% during the fourth quarter. Hilton Capital Management LLC now owns 8,038 shares of the medical research company's stock valued at $1,484,000 after purchasing an additional 380 shares during the last quarter. Impact Capital Partners LLC acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth $422,000. Truvestments Capital LLC raised its holdings in shares of Charles River Laboratories International by 6.4% during the fourth quarter. Truvestments Capital LLC now owns 2,562 shares of the medical research company's stock worth $473,000 after purchasing an additional 155 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Charles River Laboratories International by 10.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,673 shares of the medical research company's stock worth $309,000 after buying an additional 155 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several research firms recently weighed in on CRL. Citigroup upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and increased their price objective for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. Robert W. Baird dropped their price target on Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a research report on Thursday, February 20th. UBS Group restated a "neutral" rating and set a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. William Blair lowered Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 22nd. Finally, Barclays reduced their price target on shares of Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating for the company in a report on Tuesday, February 18th. One analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $189.77.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, CEO James C. Foster acquired 6,075 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was purchased at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the transaction, the chief executive officer now owns 183,639 shares of the company's stock, valued at $30,302,271.39. The trade was a 3.42 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Birgit Girshick bought 1,514 shares of the stock in a transaction on Thursday, February 20th. The shares were acquired at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Price Performance

Shares of NYSE CRL traded up $1.94 during trading on Friday, hitting $167.29. The company had a trading volume of 1,638,932 shares, compared to its average volume of 723,009. The business's 50-day moving average is $166.49 and its 200 day moving average is $183.98. The company has a market cap of $8.55 billion, a P/E ratio of 1,115.26, a PEG ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 52 week low of $150.79 and a 52 week high of $274.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same quarter in the prior year, the firm earned $2.46 EPS. The firm's quarterly revenue was down 1.1% on a year-over-year basis. Equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).